Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma.

[1]  H. Fujii,et al.  Macrophages in tumor‐draining lymph node with different characteristics induce T‐cell apoptosis in patients with advanced stage‐gastric cancer , 2003, International journal of cancer.

[2]  H. Okamura,et al.  Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL‐18 , 2003, International journal of cancer.

[3]  U. Yamashita,et al.  Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18—stimulated macrophages mediated by interferon-γ regulated by nitric oxide , 2003 .

[4]  M. Boermeester,et al.  Immune Responses and Prediction of Major Infection in Patients Undergoing Transhiatal or Transthoracic Esophagectomy for Cancer , 2003, Annals of surgery.

[5]  M. Sabel,et al.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.

[6]  H. Kuwano,et al.  Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. , 2002, Cancer letters.

[7]  Jan Spillner,et al.  The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions , 2002, Perfusion.

[8]  N. Tsuji,et al.  Serum Interleukin-18 Concentrations in Patients With Inflammatory Bowel Disease , 2002, Journal of immunotherapy.

[9]  H. Mühl,et al.  Expression and Release of IL-18 Binding Protein in Response to IFN-γ1 , 2001, The Journal of Immunology.

[10]  D. Yoon,et al.  Enhanced IL-18 expression in common skin tumors. , 2001, Immunology letters.

[11]  B. Widegren,et al.  Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma , 2001, Cancer Immunology, Immunotherapy.

[12]  T. Majima,et al.  Preoperative serum interleukin‐18 level as a postoperative prognostic marker in patients with gastric carcinoma , 2001, Cancer.

[13]  H. Hirai,et al.  In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice , 2001, Gene Therapy.

[14]  R. Merendino,et al.  Serum Levels of Interleukin-18 and sICAM-1 in Patients Affected by Breast Cancer: Preliminary Considerations , 2001, The International journal of biological markers.

[15]  D. Yoon,et al.  Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Lotze,et al.  Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. , 2001, Cancer research.

[17]  B. Piqueras,et al.  Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. , 2000, Immunology letters.

[18]  U. Studer,et al.  Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. , 2000, The Journal of urology.

[19]  M. Vaghi,et al.  Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. , 2000, Journal of biological regulators and homeostatic agents.

[20]  H. Okamura,et al.  Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. , 2000, Cancer research.

[21]  J. Renauld,et al.  Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-181 , 2000, The Journal of Immunology.

[22]  I. Sugawara,et al.  Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. , 2000, Microbes and infection.

[23]  H. Okamura,et al.  Elevated interleukin (IL)‐18 levels during acute graft‐versus‐host disease after allogeneic bone marrow transplantation , 2000, British journal of haematology.

[24]  M. Merville,et al.  Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells , 2000, Cancer Gene Therapy.

[25]  M. Kurimoto,et al.  Antitumor Activity of Interleukin-18 on Mouse Glioma Cells , 2000, Journal of immunotherapy.

[26]  Hiroshi Yamamoto,et al.  Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells , 2000, Cancer Gene Therapy.

[27]  S. Akira,et al.  IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Okamura,et al.  Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. , 1999, Anticancer research.

[29]  K. Kohno,et al.  Oversecretion of IL‐18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity , 1999, British journal of haematology.

[30]  B. Piqueras,et al.  Modulation of interleukin‐18 expression in human colon carcinoma: Consequences for tumor immune surveillance , 1999, International journal of cancer.

[31]  M. Micallef,et al.  Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration , 1999, Cancer Gene Therapy.

[32]  M. Kurimoto,et al.  Antitumor Effects on Mouse Melanoma Elicited by Local Secretion of Interleukin-12 and Their Enhancement by Treatment with Interleukin-18 , 1998, Cancer investigation.

[33]  Y. Tabata,et al.  Delivery of interleukin-12 in gelatin hydrogels effectively suppresses development of transplanted colonal carcinoma in mice , 2002, Cancer Chemotherapy and Pharmacology.

[34]  T. Yoshimoto.  Interleukin-18 (IL-18), although anti-allergic when administered with IL-12, stimulates IL-4 and histamine release by basophils , 1999 .

[35]  K. Kohno,et al.  Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. , 1998, Clinical immunology and immunopathology.